We are very proud to see that the interdisciplinary molecular imaging group of the University of Gottingen, in cooperation with the Max-Planck-Institute of Experimental Medicine, has chosen our SoftScan breast imaging system to conduct world-class research in the field of translational oncology and radiology and to have them among our growing base of clients, said Sébastien Gignac, chairman & CEO of ART. The fact that the Interdisciplinary Imaging Group Gottingen, in which radiologists, oncologists, physicists, molecular biologists, imaging scientists and chemists work in close collaboration, has ordered a SoftScan system is testimony to the power of our technology to address the needs of leading researchers in the field of oncology, added Gignac.
We feel that ART’s time domain technology will allow us to find novel imaging diagnostics for individual therapies to mark further advances towards a more personalized medicine in oncology, said Dr. Christoph Engelke, Department of Diagnostic Radiology, and Professor Frauke Alves, Department of Hematology and Oncology, University Medical Center Gottingen.
